63827 Impact on Multiple Inflammatory Axes Drives a High Level of Efficacy to Upadacitinib: Biomarker Analysis from LEVEL-UP, a Phase 3b/4 Head-to-Head Study with Dupilumab - 01/09/25
Doi : 10.1016/j.jaad.2025.05.897
Kilian Eyerich, MD, PhD
Department of Dermatology, Faculty of Medicine, Albert-Ludwigs-Universität Freiburg, Freiburg
Christopher Bunick, MD, PhD
Department of Dermatology and Program in Translational Biomedicine, Yale University School of Medicine, New Haven, Connecticut
Bruce Strober, MD, PhD
Department of Dermatology, Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, Connecticut of Medicine
Le texte complet de cet article est disponible en PDF.
| Commercial Disclosure: K. Eyerich declares acting as a consultant and investigator for: Abbvie, Almirall, BMS, Boehringer Ingelheim, Leo, Lilly, Janssen, Incyte, Sitry, Sanofi, Novartis, UCB SG Kwatra is an advisory board member or consultant for Abbvie, Celldex Therapeutics, I. |
© 2025
Publié par Elsevier Masson SAS.
Vol 93 - N° 3S
P. AB226 - septembre 2025 Retour au numéro
Article précédent
- 64181 Impact of vunakizumab on metabolic parameters and body mass index in moderate-to-severe plaque psoriasis patients with or without comorbidities: a post-hoc analysis of a phase III trial
- Xiaoguang Zhang, Yanling Li, Lihua Zhang
- 63159 Implementation of Interdisciplinary Approaches in a Dermatology Residency Program
- Dina Zamil, Nicole Nyamongo, Alexandria Brown Marrs, Joanne Jacob, Soo Jung Kim
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?